Background: The Immune Checkpoint Inhibitor Score (IChIS), an inflammation-based biomarker incorporating neutrophil and immature granulocyte counts, was recently developed to predict outcomes in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). However, evidence re...
Ismail Dilli, E. E. Kavak, M. Atak et al.· Journal of Clinical Medicine· 0 citations
BACKGROUND
This study evaluated the real-world efficacy, safety, and prognostic factors associated with progression-free survival (PFS) in patients with HR-positive/HER2-negative metastatic breast cancer treated with ribociclib.
RESEARCH DESIGN AND METHODS
This retrospective single-center study included 110 patients...
Salih Karatlı, D. Yazılıtaş, Mustafa Altınbaş· Expert Review of Anticancer...· 0 citations
FCR is a major psychosocial concern among breast cancer survivors, particularly in younger patients, those with chemotherapy history, and those with greater psychological symptom burden.